WELLINGTON MANAGEMENT CO LLP 13D and 13G filings for Akebia Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-08-10 07:57 am Sale |
2021-07-30 | 13G | Akebia Therapeutics, Inc. AKBA |
WELLINGTON MANAGEMENT CO LLP | 711 0.000% |
-12,589,752 (-99.99%) |
Filing |
| 2021-02-03 1:33 pm Sale |
2020-12-31 | 13G | Akebia Therapeutics, Inc. AKBA |
WELLINGTON MANAGEMENT CO LLP | 12,590,463 8.710% |
-5,107,650 (-28.86%) |
Filing |
| 2020-11-10 09:02 am Purchase |
2020-10-30 | 13G | Akebia Therapeutics, Inc. AKBA |
WELLINGTON MANAGEMENT CO LLP | 17,698,113 12.350% |
17,698,113 (New Position) |
Filing |